Reuters logo
BRIEF-Eli Lilly says galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine
September 8, 2017 / 11:21 AM / 15 days ago

BRIEF-Eli Lilly says galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine

Sept 8 (Reuters) - Eli Lilly And Co

* Eli Lilly And Co - Lilly’s galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine

* Eli Lilly And Co - plans to submit a Biologics License Application to U.S. Food And Drug Administration (FDA) for galcanezumab in second half of 2017

* Eli Lilly And Co - there was no clinically meaningful difference in rate of adverse events between galcanezumab 120 mg and 240 mg dosing groups in trial​

* Eli Lilly And Co - ‍in study, 4.8 percent of patients discontinued treatment due to adverse events​

* Eli Lilly And Co - ‍serious adverse events were reported by three patients in 120 mg dosing group and seven patients in 240 mg group​

* Eli Lilly - ‍over 12-month treatment period, galcanezumab associated with statistically significant reduction in number of monthly migraine headache days with both doses​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below